Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Alzheimers Dement. 2013 Oct;9(5 Suppl):S72-83. doi: 10.1016/j.jalz.2012.10.007. Epub 2013 Jan 30.
To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs).
Florbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative.
Florbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty-four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E ε4 carrier status.
: The data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.
评估氟代脱氧葡萄糖 F18 正电子发射断层扫描（PET）在阿尔茨海默病（AD）、轻度认知障碍（MCI）和健康对照受试者（HCs）中的性能特征。
在一项多中心 2 期研究中，184 名受试者（45 名 AD 患者、60 名 MCI 患者和 79 名 HCs）接受了氟代脱氧葡萄糖 PET 扫描。淀粉样蛋白负担通过视觉和定量评估进行评估，并分为阳性或阴性。
氟代脱氧葡萄糖 PET 视觉评分显示，76%的 AD 患者、38%的 MCI 患者和 14%的 HCs 存在淀粉样蛋白阳性。使用定量阈值，84%的 AD 患者、45%的 MCI 患者和 23%的 HCs 被分类为淀粉样蛋白阳性。淀粉样蛋白阳性和平均皮质淀粉样蛋白负荷与年龄和载脂蛋白 E ε4 携带状态相关。
这些数据与 AD 和 MCI 临床诊断个体中预期的淀粉样蛋白阳性率一致，表明氟代脱氧葡萄糖 F18 PET 作为临床诊断辅助手段具有潜在价值。
